featured
Vedolizumab for Preventing Intestinal Acute GVHD After Allogeneic HSCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Nat. Med. 2024 Jun 06;[EPub Ahead of Print], YB Chen, M Mohty, R Zeiser, T Teshima, O Jamy, J Maertens, D Purtill, J Chen, H Cao, G Rossiter, J Jansson, Y FløisandFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.